Lineage Cell Therapeutics (LCTX) EBT (2010 - 2026)
Lineage Cell Therapeutics posted quarterly EBT of -$7.2 million for Q1 2026, down 19.26% year-on-year from -$8.9 million in Q1 2025, and down 144.46% on a QoQ basis from $16.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) has 17 years of EBT data on file, last reported at -$7.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 19.26% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at -$13.8 million (up 23.73% YoY), and the FY2025 full-year result was -$68.6 million, down 269.43% from the prior year.
- EBT for Q1 2026 stood at -$7.2 million, down from $16.2 million in the prior quarter.
- Across five years, EBT topped out at $16.2 million in Q4 2025 and bottomed at -$19.3 million in Q2 2025.
- The 5-year median for EBT is -$6.0 million (2025), against an average of -$5.1 million.
- The widest annual swing landed in 2022, when EBT slumped 389.85%; it then surged 597.45% in 2025.
- A 5-year view of EBT shows it stood at -$6.4 million in 2022, then gained by 25.9% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then soared by 597.45% to $16.2 million in 2025, then sank by 144.46% to -$7.2 million in 2026.
- The last three EBT figures came in at -$7.2 million (Q1 2026), $16.2 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Lineage Cell Therapeutics | 325.89 Mn | 261.99 Mn | 1.73 Mn | -7.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.19 Mn |
| Dec 31, 2025 | 16.17 Mn |
| Sep 30, 2025 | -3.42 Mn |
| Jun 30, 2025 | -19.33 Mn |
| Mar 31, 2025 | -6.03 Mn |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | -7.16 Mn |
| Jun 30, 2023 | -5.20 Mn |
| Mar 31, 2023 | -6.21 Mn |
| Dec 31, 2022 | -6.36 Mn |
| Sep 30, 2022 | -5.58 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | -28.01 Mn |
| Sep 30, 2021 | -8.85 Mn |
| Jun 30, 2021 | -4.97 Mn |
| Mar 31, 2021 | -1.45 Mn |
| Dec 31, 2020 | 984,000.00 |
| Sep 30, 2020 | -7.95 Mn |
| Jun 30, 2020 | -6.53 Mn |
| Mar 31, 2020 | -8.43 Mn |
| Dec 31, 2019 | -5.34 Mn |
| Sep 30, 2019 | -17.51 Mn |
| Jun 30, 2019 | -31.30 Mn |
| Mar 31, 2019 | 34.91 Mn |
| Dec 31, 2018 | -45.33 Mn |
| Sep 30, 2018 | 66.54 Mn |
| Jun 30, 2018 | -4.65 Mn |
| Mar 31, 2018 | -63.70 Mn |
| Dec 31, 2017 | -76.84 Mn |
| Sep 30, 2017 | 18.76 Mn |
| Jun 30, 2017 | -16.10 Mn |
| Mar 31, 2017 | 50.90 Mn |
| Dec 31, 2016 | -7.74 Mn |
| Sep 30, 2016 | 29.27 Mn |
| Jun 30, 2016 | 21.23 Mn |
| Mar 31, 2016 | -24.00 Mn |
| Dec 31, 2015 | -17.93 Mn |
| Sep 30, 2015 | -17.69 Mn |
| Jun 30, 2015 | -13.27 Mn |
| Mar 31, 2015 | -13.77 Mn |
| Dec 31, 2014 | -15.00 Mn |
| Sep 30, 2014 | -12.26 Mn |
| Jun 30, 2014 | -12.91 Mn |
| Mar 31, 2014 | -11.08 Mn |
| Dec 31, 2013 | -29.34 Mn |
| Sep 30, 2013 | -10.26 Mn |
| Jun 30, 2013 | -8.20 Mn |
| Mar 31, 2013 | -8.41 Mn |
| Dec 31, 2012 | -7.06 Mn |
| Sep 30, 2012 | -5.95 Mn |
| Jun 30, 2012 | -6.08 Mn |
| Mar 31, 2012 | -5.92 Mn |
| Dec 31, 2011 | -5.45 Mn |
| Sep 30, 2011 | -4.23 Mn |
| Jun 30, 2011 | -4.98 Mn |
| Mar 31, 2011 | -4.03 Mn |
| Dec 31, 2010 | -3.76 Mn |
| Sep 30, 2010 | -2.46 Mn |